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Abstract
Background: This study assessed pharmacy performance and satisfaction as reported by patients during ovulation induction
therapy.
Materials and methods: Patients (n = 1269) receiving gonadotropin prescriptions for intrauterine insemination or in vitro
fertilisation-embryo transfer in 2007–2008 were prospectively interviewed by nurses and/or completed a structured
questionnaire to evaluate pharmacy performance. "Community" (n = 12) and "specialty" (n = 2) pharmacy status (C vs. S) was
defined by each pharmacy, and all pharmacies were selected by patients before cycle start. Patient comments about their
pharmacy were classified into five types: i) Dispensing error-gonadotropin, ii) Dispensing error-non gonadotropin, iii) Mistake
in prescribed medical equipment/supplies, iv) Counselling/communication inaccuracy, and v) Inventory problem or other.
Results: 391 pharmacy concerns were reported from 150 fertility patients during the study period. The majority (75.9%) of
patients selected a S pharmacy to fill their prescriptions, and this pharmacy type was identified in 2.8% of adverse pharmacy
encounters (p < 0.0001). Non-gonadotropin prescriptions filled at C pharmacies accounted for 40.2% of all complaints, followed
by problems with prescriptions for supplies (20.2%) and gonadotropins (18.7%) at C pharmacies. Patient conflict involving S
pharmacies was limited (n = 11), and related to operating hours and medication delivery logistics.
Conclusion: Fertility patients reported a disproportionate and significantly higher number of adverse pharmacy encounters
from C pharmacies compared to S pharmacies. Although no licensing mechanism in Ireland currently recognises special training
or certification in any area of pharmacy practice, informal self-designations by pharmacies remain a useful discriminator. Level
of familiarity with fertility medicines and availability of inventory are important characteristics to be considered when counselling
fertility patients about pharmacy choice. Those who select a C pharmacy should be advised to allow extra time for inventory
verification, order confirmation, and additional counselling. Additional study is needed to determine if a minimum volume of
fertility-related prescriptions is necessary to assure competence in this particular field of pharmacy practice.
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Background
Emotional stress associated with infertility (and the phar-
maceutical interventions intended to treat it) can be con-
siderable for some patients. Failure of IVF treatment after
multiple attempts can be especially devastating for cou-
ples [1]. Patient unfamiliarity with gonadotropin self-
injection, hormone supplements, and other medicine
required for ovulation induction cycles represent impor-
tant potential stressors of the infertility treatment experi-
ence. The occurrence of any adverse pharmacy encounter
(including dispensing error) reduces confidence in treat-
ment precision and contributes to increased patient anxi-
ety. While prior research has focused on self-reported
physical and/or emotional issues related to fertility treat-
ment [2], there has been no specific evaluation of phar-
macy encounters in the infertility stress equation.
Developing effective interventions for pharmacists is
predicated on an understanding of exact needs from the
patient's perspective [3], and pharmacy communication is
an important part of fertility treatment. In this investiga-
tion, we sought to evaluate patient satisfaction with phar-
macy services provided during advanced fertility
treatment with a view to estimate the frequency and type
of pharmacy problems encountered.
Methods
This study analysed data from 1,269 advanced fertility
treatment cycles at Sims IVF Clinic in Dublin, prospec-
tively gathered during 2007 and 2008. Feedback question-
naires and notes from structured nursing interviews with
patients (as entered into the medical record) were
reviewed for patients undergoing gonadotropin therapy
to evaluate satisfaction with pharmacy services. These data
captured patient-generated alerts involving pharmacies
involved with dispensing medication for all intrauterine
insemination and in vitro fertilisation-embryo transfer
treatment cycles, irrespective of status as new or return
patients.
Charts were assessed for documentation to confirm each
patient's pharmacy choice was made independently and
prescriptions were tracked to determine which pharmacy
that the patient selected to fill her medication order. All
communication received from pharmacies (either tele-
phonically or in writing) was also reviewed for the study
interval. Pharmacy events reported by patients were
assigned to one of the following encounter types: Cate-
gory I – Dispensing error (gonadotropin), Category II –
Dispensing error (non-gonadotropin), Category III – Dis-
pensing error (medical equipment/supplies), Category IV
– Counselling or communication inaccuracy, or Category
V – Inventory problem or problem not otherwise speci-
fied.
Although some fertility patients generated multiple com-
plaints, each issue was separately detailed to facilitate
management and analysis; each specific problem or com-
plaint lodged by a fertility patient was recorded only once.
Data on patient satisfaction with pharmacy service were
stratified by pharmacy type, either "community" (C) or
"specialty" (S). This was an unofficial designation made
by the pharmacy itself; in cases where pharmacy status
was unknown or uncertain, a member of our nursing staff
directly communicated with the relevant pharmacy man-
ager for clarification and subsequent status assignment.
A total of twelve C and two S pharmacies were subjects of
comment by fertility patients during the study interval.
Pharmacy self-designation status remained unchanged for
any retail pharmacy that appeared in both study years. No
patient used a combination of the two pharmacy types
during any fertility treatment sequence. Records describ-
ing patient-pharmacy encounters with pharmacies out-
side the Republic of Ireland were not considered for
assessment. Data were analysed by Student's t-test or z-test
for proportions, as appropriate.
Results
During the two year study period, 75.9% of patients
selected an S pharmacy and 24.1% selected a C pharmacy
to dispense their medicines (p  < 0.0001). Our quality
management system tracked 391 individual pharmacy
complaints or concerns from 150 fertility patients during
this interval, corresponding to an overall pharmacy com-
plaint rate of 11.8%. Study patients distributed their pre-
scriptions among 12 C and 2 S pharmacies in 2007 and
2008. C and S pharmacies accounted for 97.2 and 2.8% (p
< 0.0001) of adverse pharmacy encounters, respectively,
as shown in Figure 1.
We sought to identify any possible common features in
the smaller S pharmacy complaint group (n = 11) first. All
eleven adverse encounters in this sub-set involved dissat-
isfaction with limited office hours, complaints about the
inability to provide home or workplace delivery, or other
logistical issues that could not be resolved (Type V). No
other encounter type involving S pharmacies was reported
by study patients.
The sample deriving from fertility patients who chose a C
pharmacy was studied next (see Figure 2). In this group,
errors involving non-gonadotropin prescriptions (Type II)
accounted for 40.8% of complaints (n = 155), including
incorrectly filled prescriptions for anti-coagulants,
immune modulators, antibiotics, vitamins and/or narcot-
ics. Among our fertility patients, 20.3% of C pharmacy
service concerns involved problems with prescribed med-
ical equipment or supplies (Type III), including wrong
needle size, insufficient number of syringes dispensed,
failure to provide the "safe sharps bin", or in one case, the
refusal to dispense any equipment for subcutaneous injec-International Archives of Medicine 2009, 2:24 http://www.intarchmed.com/content/2/1/24
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tion of gonadotropin. In 18.7% of unsatisfactory phar-
macy encounters, our fertility patients experienced
problems with specific gonadotropin prescriptions
(Type I).
Type IV encounters, defined as flawed or inadequate
patient counselling from the pharmacist, were experi-
enced by 15.5% of our sample (n = 59). These included
complaints about the pharmacy providing wrong infor-
mation on drug manufacture status and availability (e.g.,
being told a medication had been discontinued), failure
to advise about need to refrigerate, and misstatements
regarding the government DPS scheme's exclusion of fer-
tility medications. No patient complaint was received
involving any pharmacy's pricing of medicine or supplies.
From patients who used a C pharmacy, there were an
additional 19 unsatisfactory occurrences (5%) that could
not be classified (Type V). The pharmacy service com-
plaint type did not vary significantly from 2007 to 2008
(see Figure 3).
Discussion
The roles and responsibilities of pharmacists are changing
rapidly in the current health care environment [4]. Partic-
ularly for patients with chronic conditions like diabetes
[5], cardiovascular or renal disease [3,6], migraine [7],
asthma [8], rheumatoid arthritis [9], or long-term psychi-
atric illness [10], the patient-pharmacist relationship rep-
resents a unique opportunity for improving health
delivery and facilitating the work of other providers.
While some infertility etiologies have been classified as
chronic [11,12], the patient-pharmacist dynamic has not
been specifically studied in a reproductive medicine con-
text until now.
Source of adverse pharmacy encounter alerts generated by  Irish fertility patients during 2007 and 2008, by pharmacy  type (n = 391) Figure 1
Source of adverse pharmacy encounter alerts gener-
ated by Irish fertility patients during 2007 and 2008, 
by pharmacy type (n = 391).
Distribution of community pharmacy complaints (n = 391) by  fertility patients Figure 2
Distribution of community pharmacy complaints (n = 
391) by fertility patients.
Frequency of adverse pharmacy encounters reported by fer- tility patients (n = 150) during a two year audit Figure 3
Frequency of adverse pharmacy encounters reported 
by fertility patients (n = 150) during a two year audit. 
Type 1 = Dispensing error-gonadotropins; Type 2 = Dispens-
ing error-non gonadotropin; Type 3 = Dispensing error 
involving medical equipment/supplies; Type 4 = Counselling/
communication error; Type 5 = Inventory problem or not 
otherwise specified. No significant difference was observed 
between 2007 and 2008 for any event type (p > 0.20, by z-
test for proportions, CI 95%). Note: Some patients generated 
more than one complaint, but each complaint was assigned 
to only one type.International Archives of Medicine 2009, 2:24 http://www.intarchmed.com/content/2/1/24
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The current investigation yielded several unanticipated
findings. We found fertility patients in Ireland can be a
useful source of direct information about pharmacy per-
formance. These patients, in general, are motivated and
have a good level of personal knowledge about their own
treatment plan and associated medications. However,
while some adverse pharmacy encounters reported by our
patients did not reach crisis level, the issues lodged did
occasionally identify actual dispensing errors. Pharmacy
mistakes of this kind can have disastrous reproductive
consequences if uncorrected, as previously reported [13].
In the current sample, C pharmacies were responsible for
a disproportionate share of unsatisfactory encounters
reported by patients. But interestingly, the most common
pharmacy error type did not involve gonadotropins. It
was surprising to record the highest level of dispensing
error (40.8%) in prescriptions for anti-coagulants, ster-
oids, vitamins, antibiotics or other adjunctive non-fertility
agents to our patients.
Since the frequency of service-related issues has not been
previously published for any large population of fertility
patients, our observed rate of adverse pharmacy encoun-
ters (11.8%) could not be benchmarked against other ref-
erence groups for comparison. Although this centre's
quality management apparatus is designed with a sensitiv-
ity threshold to detect problems more subtle than adverse
drug events, a large study confined to serious insulin dos-
ing errors during 2000 and 2001 found such problems to
be "common" [14].
The second most frequent error type reported by patients
dealt with medical equipment or supplies, which repre-
sented 20.3% of all adverse pharmacy encounters among
our fertility patients (Type III). These complaints typically
involved the C pharmacy providing the incorrect gauge
needle (or dispensing an insufficient quantity of the
proper needle) used for subcutaneous injection of pre-
scribed medication. Patients were also inconvenienced by
the unwillingness or inability of C pharmacies to provide
biohazard receptacles ("safe sharps bin"), which necessi-
tated the patient calling the IVF clinic for further advice.
About 18% of patient complaints alerted us major prob-
lems with the gonadotropin prescription itself (Type I).
This included incorrect drug being dispensed, label-pre-
scription mismatch, and inappropriate concentration/
wrong delivery device. In this group of complaints fertility
patients registered substantial worry, perhaps because the
gonadotropins were regarded as the most critical ingredi-
ent in their fertility treatment sequence.
While these data offer a novel perspective on interactions
between fertility patients and their pharmacists, some of
our findings should be interpreted with caution. We were
only able to evaluate two "specialty" pharmacies used by
these study patients, and additional pharmacies of this
type should be included in future investigations. It is also
important to differentiate an "adverse drug event" from
"pharmacy complaint". To be sure, some complaints
made by patients were dangerous dispensing errors. Yet
the combination of nursing and medical staff surveillance
together with fertility patients who asserted active roles in
their own medical care intercepted these problems before
they escalated to the level of patient injury. Nevertheless,
this study confirms the vital role for prevention in strate-
gies to reduce pharmacy error in the delivery of advanced
reproductive treatments. Since patients may have been
less likely to lodge a complaint against a pharmacy if they
selected it themselves, the actual frequency of adverse
pharmacy encounters may actually be higher than we
observed. Finally, electronic prescribing is not widely used
in Ireland and each prescription must be physically
brought to the pharmacy. This "hand carrying" of pre-
scriptions may not necessarily have been by the patient
herself, and it was not possible to discern which (if any)
pharmacy service complaints were initiated by a husband
or other family member. Increased use of information
technologies in prescribing and dispensing medications
should lower the rate of adverse pharmacy encounters and
medication errors in Ireland.
How fertility patients select a particular pharmacy is a
complex matter, and factors influencing pharmacy choice
will differ depending on practice region. Yet, interviews
with fertility patients here suggest that convenience is by
far the most important consideration. The consistent pat-
tern of Type V complaint regarding S pharmacies observed
in this study tends to support this hypothesis. We found
some C pharmacies performed exceptionally well and
demonstrated a high rate of patient satisfaction, while
some S pharmacies did not meet key patient expectations.
However, the frequency of unsatisfactory pharmacy
encounters was significantly higher when fertility patients
did not select an S pharmacy. In Ireland, physicians are
not permitted to recommend any pharmacist or retail
pharmacy business "otherwise than in the exercise of his
or her professional judgment" [15]. Yet the current study
brings some important questions into focus both for phy-
sicians and pharmacists: What makes a pharmacy desig-
nate itself as a "community" or "specialty" pharmacy? Is
there a minimum volume of fertility-related prescriptions
that a pharmacy should dispense to maintain proficiency
in this specific branch of pharmacy practice? Are physi-
cians ethically obligated to guide a fertility patient's
choice of pharmacy, considering the profound difference
in medication error risk identified in this research? This
study, believed to be the first of its kind, brings into sharp
relief how fertility patients perceive S and C pharmacies in
Ireland differently, and suggests a multidisciplinary
approach for further investigations. Differences in fertilityPublish with BioMed Central    and   every 
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patient satisfaction by pharmacy type will be difficult to
explain without such study.
Conclusion
As the number of patients seeking reproductive treatment
increases, the number of fertility-related prescriptions will
also grow. How these prescriptions are dispensed will
continue to be an important issue not just for health econ-
omists but clinicians too, in an attempt to demonstrate
effectiveness of the patient-pharmacist dynamic [16].
Although the "specialty" vs. "community" pharmacy
nomenclature is informal, this is an Irish tradition
unlikely to be discontinued. It was outside the scope of
our study to define or challenge these designations. The
labels did appear to be accurate and provided useful
descriptive information about scope, effectiveness and
safety of pharmacy practice. However, the substantial dif-
ference in fertility patient satisfaction according to phar-
macy type warrants further tracking, and forms the basis
of ongoing research at our institutions.
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